Medical Doctor of Jinan University, Outstanding Entrepreneur of Guangdong Province, Innovation Talent of Tianhe District, Guangzhou, Member of the 8th GuangzhouTianhe District Committee of the Chinese People's Political Consultative Conference, Leader of a number of major national, provincial, and municipal science and technology projects，owner of multiple invention patents, with more than 20 years of clinical and CRO management experience.

Bachelor of Chinese Pharmacology from China Pharmaceutical University; Master of Pharmacology from Sun Yat-sen University; Engaged in the new drug research industry for more than 20 years and has rich experience in drug evaluation and new drug research and development; Deputy general manager and director of the Drug Evaluation Center (GLP) of Boji, in charge of preclinical research.

Clinical Trial Methodology (DME) Specialist, Statistical Specialist; 1995-1997, Jinan Fifth People's Hospital; Resident Physician 2003-2012; Guangzhou University of Traditional Chinese Medicine, Associate Researche; joined Guangzhou Boji Medical Biotechnology Co., Ltd. in 2009

Doctor of Medicine, more than 10 years of CRO business work experience.

12 years of clinical trial management experience, proficient in ICH-GCP related guidelines.

Senior expert in clinical research on medical devices, participating in more than 300 tests of artificial organs, cardiovascular and cerebrovascular devices, tumor devices, dressings, anti-adhesion, blood purification, rehabilitation devices and old in vitro diagnostic reagents. Li Qiang published more than thirty academic papers, a medical monograph and participated in the preparation of four medical professional books and three medical device books.

1994-2000 Senior Reviewer of the US Food and Drug Administration (FDA). From 2000 to 2005, he was the Senior Director of United Healthcare, Hong Kong Hutchison Whampoa Pharmaceuticals. Since 2005, he has been serving as a pharmaceutical development consultant for several large pharmaceutical companies in Europe, America and China, leading several teams from different countries, successfully completing more than 60 new drug developments and declarations, and has assisted in completing a number of technology transfers and corporate mergers and acquisitions. Visiting Professor at the University of North Carolina.

Deputy Chief Physician, Master of Science(Completion), Peking University School of Medicine, National Third-level Psychological Counselor. Graduated from the Department of Traditional Chinese Medicine of Henan University of Traditional Chinese Medicine in 1987 with a bachelor's degree in medicine. 20 years of clinical practice in Chinese medicine and neurology in primary hospitals. Wang Lingyu studied in the Department of Neurology of the Second Affiliated Hospital of Zhengzhou University and the Department of Encephalopathy of the First Affiliated Hospital of Guangzhou University of Chinese Medicine in 1994 and 2001. From 2004 to 2006, she studied in the Department of Psychological Counseling and Applied Psychology at the Peking University School of Medicine. She joined Guangzhou Boji Medical Biotechnology Co., Ltd. in 2008 engaging in clinical research of new drugs. Sheis currently responsible for the design and implementation of the company's clinical trial project, CDE communication consultation registration, and SMO-related business.

Dr.Li Xiaochuan has been engaged in drug analysis and new drug research and development and has established large-scale GLP biological analysis laboratories. He won the first prize of Shanghai Science and Technology and published more than 20 articles in internationally renowned SCI journals. He has 9 invention patents. Dr.Li Xiaochuan is responsible for completing the pharmacotoxicity studies of hundreds of new drugs and bioequivalence studies of generic drugs.

General Manager of Bo Huikang 14-year CRO experience, responsible for data management, statistics and programming (SAS, JAVA and VBA)

20-year clinical project management and operation experience; Ma Chunbo participated many times in national on-site assessment and post-722 national audit requirements training and has extensive on-site audit experience. His pass rate reached 100%.